Filed Pursuant to Rule 424(b)(5)
Registration No. 333-280667
PROSPECTUS SUPPLEMENT
(To Prospectus dated July 19, 2024)
IMMURON LIMITED
Up to $2,006,769
American Depositary Shares Representing Ordinary
Shares
This prospectus supplement
amends, supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our Offering Agreement
prospectus dated July 19, 2024, which together with the accompanying base prospectus dated July 19, 2024 contained in our Registration
Statement on Form F-3 (Registration No. 333-280667), which we refer to as the prospectus, relating to the offering, issuance, and sale
of our American Depositary Shares (each, an “ADS” and, collectively the “ADSs”) representing our ordinary
shares that may be issued and sold from time to time under an at-the-market offering agreement dated as of July 2, 2024 (the “Offering
Agreement”) between us and H.C. Wainwright & Co., LLC (“Wainwright”). These sales, if any, will be made pursuant
to the terms of the Offering Agreement.
This prospectus supplement
should be read in conjunction with, is not complete without, and may not be delivered or utilized except in connection with, the prospectus,
including all supplements thereto and documents incorporated by reference therein. If there is any inconsistency between the information
in the prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. Any information that
is modified or superseded in the prospectus shall not be deemed to constitute a part of the prospectus, except as modified or superseded
by this prospectus supplement.
The aggregate market value of our outstanding ordinary shares held by non-affiliates as of the date of this prospectus supplement is approximately
$14,563,418, based on 8,071,202 ADS-equivalents (representing 322,848,081 ordinary shares) outstanding as of the date of this prospectus
supplement, of which 7,914,901 ADS-equivalents were held by non-affiliates, and a price per ADS of US$1.84, which was the closing sale
price of our ADS on the Nasdaq Capital Market on September 8, 2026. Pursuant to General Instruction I.B.5 of Form F-3, in no event will
we sell securities pursuant to this prospectus supplement with a value of more than one-third of the aggregate market value of our ordinary
shares held by non-affiliates in any 12 calendar month period, or $4,854,473 as of the date of this prospectus supplement. As of the date
of this prospectus supplement, we have sold approximately $2,847,703 of securities pursuant to General Instruction I.B.5 of Form F-3 during
the 12 calendar months prior to, and including, the date of this prospectus supplement, and are therefore eligible to sell up to an additional
$2,006,769 of our securities pursuant to General Instruction I.B.5 of Form F-3. Pursuant to General Instruction I.B.5 of Form F-3, in
no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than
one-third of the aggregate market value of our voting and non-voting common equity held by non-affiliates in any 12 calendar month period
so long as our public float remains below $75 million.
We are filing this prospectus
supplement to supplement and amend, as of October 23, 2026, the prospectus, as supplemented, to decrease the maximum aggregate offering
price of our securities that may be offered, issued and sold under the prospectus, as supplemented and amended by this prospectus supplement,
pursuant to the Offering Agreement with Wainwright to approximately $2,006,769. From and after the date hereof, pursuant to General Instruction
I.B.5 of Form F-3, we are offering to issue and sell up to approximately $2,006,769 of securities from time to time through Wainwright,
acting as our sales agent or principal in accordance with the Offering Agreement.
Our ADSs are listed on The
Nasdaq Capital Market under the symbol “IMRN.” Each ADS represents 40 of our ordinary shares, no par value per share. On October
22, 2026, the last reported price of our ADSs on The Nasdaq Capital Market was $0.97 per ADS. Our ordinary shares are currently listed
on the Australian Securities Exchange, or ASX, under the symbol “IMC.” On October 22, 2026, the last reported price of our
ordinary shares on the ASX was A$0.04 per ordinary share.
Sales of ADSs, if any, under
this prospectus supplement and accompanying prospectus may be made in sales deemed to be “at the market offerings” as defined
in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act. Wainwright is not required to sell any specific number
or dollar amount of ADSs but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales
practices, on terms mutually agreed to by Wainwright and us. There is no arrangement for funds to be received in any escrow, trust or
similar arrangement.
We will pay Wainwright a cash
commission equal to 3.0% of the gross sales price of the ADSs sold by Wainwright under the Offering Agreement. In connection with
the sale of the ADSs on our behalf, Wainwright will be deemed to be an “underwriter” within the meaning of the Securities
Act and the compensation paid to Wainwright will be deemed to be underwriting commissions or discounts. We have also agreed to provide
indemnification and contribution to Wainwright with respect to certain liabilities, including liabilities under the Securities Act.
Investing in our securities
involves a high degree of risk. Before buying any of our securities, you should carefully consider the risk factors described in “Risk
Factors” beginning on page 4 of the Offering Agreement prospectus dated July 19, 2024, and under similar headings in other documents
that are incorporated by reference into this prospectus supplement and the prospectus.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
supplement is truthful or complete. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
The date of this prospectus supplement is October
23, 2026.
